• Red Light Oregon, Inc. and Red Light Holland Corp. (TRIP) release market research findings that reveals a potential micro dosing services market of US$1 billion
  • Research showed at least 16 per cent of adults in Oregon are interested in micro-dosing services on a weekly basis and 47 per cent of those were interested in “Micro dosing in a Mindfulness workshop”
  • Combining the findings with 16 per cent of the adult population in Oregon times US$50 per week times 52 weeks equals a potential market size of more than US$1 billion
  • Measure 109 will make Psilocybin Services available to 21 years and older in Oregon
  • Red Light Holland Corp. (TRIP) is unchanged trading at $0.195 per share at 3:21 p.m. ET

Market research by Red Light Holland (TRIP) reveals an estimated US$1 billion micro-dosing services market in Oregon.

The market research used an online survey with 13 questions answered by 473 Oregonians.

The survey revealed that at least 16 per cent of adults in Oregon are interested in micro-dosing services on a weekly basis or more.

Forty-seven per cent of those interested in micro-dosing were interested in “Micro dosing in a Mindfulness workshop”.

The preferred price for the services averaged above US$50 per week.

When combining the information with the adult population size of Oregon, a calculation of 2,429,348 times 16 per cent adults interested in micro-dosing weekly times US$50 times 52 weeks equals US$1,010,608,768 per annum estimated market size.

Based on this data, Red Light Oregon will be reaching out to OPAB members to offer recommendations.

Measure 109 will make Psilocybin Services available to 21 years and older in Oregon without a need for medical diagnosis.

Red Light Holland Corp. (TRIP) is unchanged trading at $0.195 per share at 3:21 p.m. ET.

More From The Market Online
Psychedelic pills

Canadian psychedelic stock to supply MDMA to Yale

Canadian psychedelic stock PharmAla Biotech (CSE:MDMA) is up after signing a contract to supply MDMA for a clinical trial at Yale University.
MindBio Therapeutics chief executive officer Justin Hanka.

MindBio advances world-first psychedelic microdosing clinical trials

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Psilocybin mushrooms

Optimi will test its psilocybin on frontline healthcare workers

Health Canada clears psychedelics stock Optimi Health (CSE:OPTI) to test its psilocybin on frontline healthcare workers.
A hand holding blocks that spells out PTSD

Optimi Health ships first MDMA capsules to Australia to treat PTSD

Optimi Health (CSE:OPTI) reveals it has completed the inaugural export of its GMP-validated MDMA capsules to Australia.